Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | AQP1 | P29972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035766 | 0.75 | PTGS1 (0.59) | KDM4EKMT2AMEN1MAPK9ALDH1A1 | |
| SCHEMBL7990464 | 0.75 | MAPK9 (0.54) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL11410387 | 0.74 | PTGS1 (0.58) | KDM4EKMT2AMEN1MAPK9ALDH1A1 | |
| SCHEMBL11459800 | 0.73 | MAPK9 (0.57) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL7986595 | 0.71 | PTGS1 (0.55) | KMT2AMEN1MAPK9ALDH1A1PTGS1 | |
| SCHEMBL7987319 | 0.71 | MAPK1 (0.50) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL29785806 | 0.71 | MAPK9 (0.56) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL22722996 | 0.71 | MAPK9 (0.56) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL4510613 | 0.71 | MAPK9 (0.56) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL1154990 | 0.71 | MAPK9 (0.56) | NPC1RAB9ASMN1; SMN2HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3708957-B2 | — | — | 2005-10-19 | — | — | JP | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-0606366-A1 | SUBSTITUTED PHENSERINES AND PHENYLCARBAMATES OF (-)-ESEROLINE, (-)-N1-NORESEROLINE, AND (-)-N1-BENZYLNORESEROLINE; AS SPECIFIC INHIBITORS OF ACETYLCHOLINESTERASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-07-20 | — | — | EP | claimed |
| WO-1993006105-A1 | SUBSTITUTED PHENSERINES AND PHENYLCARBAMATES OF (-)-ESEROLINE, (-)-N1-NORESEROLINE, AND (-)-N1-BENZYLNORESEROLINE; AS SPECIFIC INHIBITORS OF ACETYLCHOLINESTERASE | UNITED STATES GOVERNMENT, AS REPRESENTED BY SECRET (US) | 1993-04-01 | — | — | WO | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | DONEHEW FUND LIMITED PARTNERSHIP | 2008-10-23 | — | — | US | disclosed |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | DONEHEW FUND LIMITED PARTNERSHIP | 2008-10-23 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | KDM4E 4229/4885MAPT 2655/4885NPC1 1505/4885 |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | KDM4E 4229/4885MAPT 2958/4885NPC1 2840/4885 |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | EDNRB, EDNRA, ECE1 | KDM4E 2995/4885MAPT 4604/4885NPC1 3378/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | KDM4E 4453/4885MAPT 3078/4885NPC1 2248/4885 |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | KDM4E 3445/4885MAPT 4128/4885NPC1 2658/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | KDM4E 3799/4885MAPT 2875/4885NPC1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.